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LVH = left ventricular hypertrophy 
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ABSTRACT 
Background: Lipoprotein(a) [Lp(a)] is an established and independent risk factor for cardiovascular 
outcomes. However, the relationship of Lp(a) with risk of sudden cardiac death (SCD) is unknown. We 
aimed to assess the association of Lp(a) with risk of SCD in the Kuopio Ischemic Heart Disease 
prospective cohort study of 1,881 men aged 42-61 years at recruitment.  
Methods and Results: Plasma Lp(a) concentration was assessed at baseline and repeat measurements 
made several years apart. After a median follow-up of 24.7 years, 141 SCDs were recorded. Hazard ratios 
(HRs) (95% confidence intervals [CI]) were assessed and were corrected for within-person variability in 
Lp(a) levels. The regression dilution ratio of loge Lp(a) adjusted for age was 0.84 (95% CI: 0.81-0.88). 
Lipoprotein(a) levels were log-linearly associated with risk of SCD. In analyses adjusted for established 
risk factors, the HR (95% CI) for SCD per 1 standard deviation (3.56-fold) higher baseline loge Lp(a) was 
1.24 (1.05-1.47; P = 0.013).  This remained consistent on further adjustment for alcohol consumption, 
resting heart rate, lipids, and C-reactive protein 1.23 (1.04-1.46; P = 0.018). HRs remained unchanged 
after accounting for incident coronary events and did not vary importantly in several relevant clinical 
subgroups. Adding Lp(a) to a SCD risk prediction model did not significantly improve risk discrimination 
beyond established risk factors, but improved the continuous net reclassification 30.2% (1.1 to 59.2%, 
P=0.042). 
Conclusions: Available evidence shows a continuous and independent association between Lp(a) levels 
and risk of SCD. Further research is needed to replicate these findings.  
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1. Introduction 
Lipoprotein (a) [Lp(a)], a liver derived lipoprotein composed of a central core with apolipoprotein 
B100 (apo B100) covalently bound to apolipoprotein (a) [apo(a)],[1] is an established and independent risk 
factor for myocardial infarction (MI), coronary heart disease (CHD),stroke, heart failure, and calcific 
aortic stenosis.[2-5] There are also suggestions of causal relationships between Lp(a) and these 
outcomes.[3-5] 
Though Lp(a) pathophysiology is still not fully understood, there is evidence to suggest that that Lp(a) 
contributes to the development of CHD via pro-atherogenic and pro-inflammatory activities.[6] Sudden 
cardiac death (SCD) is a global public health problem accounting for 15-20% of all deaths[7] with CHD 
being the most common pathology underlying SCD.[8] Despite reported declines in CHD incidence over 
the past decades due to major advances in its treatment and prevention,[9, 10] SCD rates have declined to 
a lesser extent;[11] suggesting that CHD may not be the underlying cause for a fraction of SCDs. Given 
that CHD and SCD have shared risk factors[12]  and the established relationship between Lp(a) and 
CHD, we hypothesized that serum Lp(a) would be linked to the risk of SCD. In addition, though 
established atherosclerotic risk factors explain a large proportion of the risk of SCD,[13] its pathogenesis 
is still not fully established as it appears other additional factors may be involved. These established risk 
factors are often absent in a large proportion of SCD victims,[14] which makes the identification of 
individuals at increased risk a difficult undertaking. Lipoprotein(a) may represent a substantial residual 
risk in mediating SCD and could be a novel causal risk factor or a risk predictor for SCD. However, to 
date, there has been no previous prospective evaluation of the association of Lp(a) with SCD.  
To clarify this issue, our first objective was to evaluate in detail, the nature and magnitude of the 
prospective association of Lp(a) with risk of SCD in a population-based cohort of 1,881 apparently 
healthy men from eastern Finland. The second objective was to assess the consistency of the association 
in important clinical subgroups. Finally, we investigated the extent to which plasma Lp(a) measurements 
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could improve the prediction of SCD when added to conventional risk factors. In subsidiary analyses, we 
also assessed the associations of Lp(a) with out-of-hospital SCDs and non-SCDs. 
 
2. Materials and methods 
This study followed the STROBE (STrengthening the Reporting of OBservational studies in 
Epidemiology) guidelines for reporting observational studies in epidemiology.[15] 
 
2.1. Study population 
Participants in the current study consisted of a representative sample of men living in the city of Kuo-
pio and its surrounding rural communities in eastern Finland who were recruited into the Kuopio 
Ischemic Heart Disease (KIHD) risk factor study. This population-based prospective study was designed 
to investigate risk factors for CVD and other chronic diseases. Study participants were 42-61 years of age 
during baseline examinations performed between March 1984 and December 1989. Of 3433 potentially 
eligible and randomly selected men, 3235 were found to be eligible for the study. Of this number, 2682 
(82.9 %) volunteered to participate, 186 did not respond to the invitation and 367 declined to give 
informed consent. For the present analysis, men with a prevalent history of heart failure (HF) and cardiac 
arrhythmias were excluded. The current analysis included 1,881 men with non-missing information on 
plasma Lp(a), relevant covariates, and outcomes. The research protocol and study was approved by 
Research Ethics Committee of the University of Eastern Finland and each participant gave written 
informed consent.  
 
2.2. Ascertainment of outcomes 
We included all SCDs that occurred from study enrollment through to 2012. No losses to follow-up 
were recorded in the KIHD study. Participants (using Finnish personal identification codes) are under 
continuous annual surveillance for the development of new CVD events, including incident cases and 
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deaths.[16] The sources of information on SCD and other outcomes were based on a comprehensive 
review of all available hospital records, wards of health centres, informant interviews, health practitioner 
questionnaires, study electrocardiograms (ECGs), death certificate registers, and medico-legal reports. 
The diagnostic classification of SCDs was based on symptoms, electrocardiographic findings, cardiac 
enzyme elevations, autopsy findings (80% of all cardiac deaths), and history of CHD together with the 
clinical history and findings from hospital and paramedic staff. A death was determined to be an SCD 
when it occurred within 1 hour of the onset of an abrupt change in symptoms or within 24 hours after the 
onset of symptoms; including nonwitnessed cases when clinical and autopsy findings did not reveal a 
non-cardiac cause of sudden death or after successful resuscitation from ventricular tachycardia and/or 
ventricular fibrillation.[17] The witnessed subject was to have been seen alive and symptom free within 
one hour before the event. Sudden cardiac deaths that occurred in out-of-hospital conditions were also 
defined as events that occurred in places that had been reported accurately in hospital documents.[17] 
Documents were cross-checked in detail by two physicians. Cardiac deaths that did not lead to death 
during the following 24 hours of the onset of symptoms were considered as non-SCDs. The Independent 
Events Committee, masked to clinical data, performed classification of outcomes. 
 
2.3. Measurement of risk factors 
The collection of blood samples, physical measurements, lifestyle characteristics, and measurement of 
serum lipids, lipoproteins and glucose have been described in detail in previous reports.[18, 19] The 
cholesterol content of lipoprotein fractions were measured from fresh samples after combined 
ultracentrifugation and precipitation, and serum triglycerides were assessed enzymatically (Boehringer 
Mannheim, Mannheim, Germany).[20] Measurement of Lp(a) concentrations were made from frozen 
plasma samples stored at -20° C for 2-6 years, using  a radioimmunoassay (Mercodia Apo(a) RIA, 
Mercodia AB, Uppsala, Sweden). Repeat measurements of Lp(a) were performed 4 years and 11 years 
after the baseline measurements, during the follow-up period in a random subset of participants. Fasting 
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plasma glucose (FPG) was measured by the glucose dehydrogenase method (Merck, Darmstadt, 
Germany) after protein precipitation by trichloroacetic acid. C-reactive protein (CRP) was measured with 
an immunometric assay (Immulite High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA, 
USA). Standard resting 12-lead ECG was also recorded and heart rate was defined. The ECG criterion for 
left ventricular hypertrophy (LVH) was based on either the Sokolow-Lyon or Romhilt-Estes point score 
as described previously.[18, 19]  
 
2.4. Statistical analysis 
We log-transformed values of skewed variables to achieve normal distributions. Descriptive analyses 
were performed to summarize the baseline characteristics of the participants. The standard deviation (SD) 
of baseline loge Lp(a) concentration was 1.27, corresponding to approximately four-fold higher 
circulating Lp(a) (ie, e1.27=3.56). The partial correlation coefficients were calculated using linear 
regression models adjusted for age, to assess the cross-sectional associations of Lp(a) with various risk 
markers. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional 
hazard models. The assumptions of the proportionality of hazards were confirmed using Schoenfeld 
residuals.[21]  To assess the shape of the association between Lp(a) and SCD risk, HRs were calculated 
within quartiles of baseline Lp(a) and plotted against mean Lp(a) levels within each quartile. Floating 
variances were used to calculate 95% confidence intervals for the log hazard ratio in each group 
(including the reference group), to allow for comparisons across the groups irrespective of the arbitrarily 
chosen reference category (bottom quartile)26. As the association showed a continuous shape, HRs were 
calculated per 3.56-fold (ie, 1-SD) higher Lp(a) levels. In subsidiary analysis, HRs were also calculated 
by quartiles defined according to the baseline distribution of plasma Lp(a) levels. Hazard ratios were 
adjusted for age, BMI, systolic blood pressure (SBP) prevalent CHD, smoking status, history of diabetes 
mellitus, LVH, history of hypertension, use of medications (antihypertensive agents and lipid-lowering 
drugs), alcohol consumption, resting heart rate, triglycerides, high-density lipoprotein cholesterol (HDL-
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C), and CRP. We performed subgroup analyses using interaction tests to assess statistical evidence of any 
differences in hazards across levels/categories of pre-specified individual level characteristics, including 
age at survey, smoking status, history of diabetes mellitus, history of hypertension, LVH, BMI, SBP, and 
CRP. To minimize biases as a result of including possible cases with prevalent but undetected CHD, heart 
failure, and cardiac arrhythmias, sensitivity analysis involved excluding the first five years of follow-up. 
Given that most exposures in epidemiological studies are subject to fluctuations within individuals over 
time and are measured with error, analysis using only baseline measurements of the exposure could 
underestimate the true strength of any aetiological association between exposure and disease outcome (i.e. 
“regression dilution bias”[22]). We therefore quantified and corrected for within-person variability in 
levels of Lp(a), that is, the extent to which an individual’s Lp(a) measurements vary around a long-term 
average level exposure (“usual levels”);[23] which was achieved by estimating adjusted regression 
dilution ratios (RDRs), calculated by regressing available repeat measurements on baseline values.[24] 
Finally, to assess whether adding information on plasma Lp(a) measurements to established SCD risk 
factors is associated with improvement in prediction of SCD risk, we calculated measures of 
discrimination for censored time-to-event data (Harrell’s C-index [25]) and reclassification (the 
continuous net-reclassification-improvement [NRI], a category-free version of the NRI).[26] Measures of 
discrimination and reclassification were assessed for the risk model (age, SBP, cigarette smoking, serum 
low density lipoprotein cholesterol, history of diabetes, BMI, previous myocardial infarction, family 
history of CHD, and cardiorespiratory fitness) as previously described.[17, 27]All statistical analyses 
were conducted using Stata version 14 (Stata Corp, College Station, Texas). 
 
3. Results 
3.1. Baseline characteristics and correlates of lipoprotein(a) 
The mean age at entry was 53 (SD, 5) years. The median (interquartile range) of Lp(a) at baseline was 
9.66 (3.84-22.04) mg/dl (Table 1). Plasma Lp(a) levels were weakly and inversely correlated with 
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physical measures (BMI and blood pressure), triglycerides, and fasting plasma glucose. Weak positive 
correlations were observed for total cholesterol (r = 0.12) and CRP (r = 0.10). Baseline Lp(a) levels were 
significantly lower in men with diabetes compared with men without diabetes (Table 2). During a median 
(IQR) follow-up of 24.7 (19.6-26.3) years (41,071 person-years at risk), there were 141 SCDs (annual rate 
3.43/1000 person-years at risk, 95% confidence interval (CI) 2.91 to 4.05). Of the total SCDs, 109 
occurred out-of-hospital. There were 68 non-SCDs. 
 
3.2. Correction for within-person variability 
Serial measurements of Lp(a) taken 4 years and 11 years after baseline over 24.7 years, were available 
in a random sample of 633 men, providing a total of 1,176 repeat measurements of Lp(a). Overall, the 
regression RDR of loge Lp(a), adjusted for age, was 0.84 (95% CI: 0.81to 0.88), suggesting that the 
associations using one-off or baseline measurements of Lp(a) with SCD would only under-estimate the 
association by [1/0.84)-1]*100=19%. 
 
3.3. Lipoprotein(a) and risk of sudden cardiac death 
Cumulative hazard curves demonstrated a greater risk of SCDs among males in the top quartile of 
Lp(a) levels compared to those in the bottom quartile (P = 0.032 for log-rank test; Figure 1). In analysis 
adjusted for conventional risk factors (age, BMI, SBP, prevalent CHD, smoking status, history of diabetes 
mellitus, LVH, history of hypertension, use of antihypertensive agents and lipid-lowering drugs), there 
was a continuous association of Lp(a) with risk of SCD, which was potentially consistent with either a 
curvilinear or log-linear shape. However, statistical tests suggested a better fit with a log-linear shape (P 
for linearity = 0.006) (Figure 2). The HR per 1 SD change in baseline loge Lp(a) concentration was 1.24 
(95% CI: 1.05 to 1.47; P =0.013) in analysis adjusted for established risk factors, which remained 
consistent on further adjustment for alcohol consumption, resting heart rate, triglycerides, and HDL-C 
1.23 (95% CI: 1.04 to 1.46; P = 0.018) and further for CRP 1.20 (95% CI: 1.01 to 1.43; P = 0.039). The 
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HR remained materially unchanged after further adjusting for incident coronary events (Table 3). The 
positive associations were maintained in analyses by quartiles of the baseline distribution of Lp(a) levels 
(Table 3). The findings were qualitatively similar on correction for regression dilution (Appendix 
Supplement 1). Hazard ratios did not vary importantly by age, BMI, SBP, HDL-C, triglycerides, CRP, 
history of diabetes mellitus, smoking status, history of hypertension, and prevalent CHD (Figure 3), and 
the main results remained the same in analyses that excluded the first five years of follow-up (data not 
shown). A SCD risk prediction model containing established risk factors yielded a C-index of 0.7526 
(95% CI: 0.7154 to 0.7898). After addition of information on plasma Lp(a) to the model, the C-index was 
0.7531 (0.7162 to 7901), yielding a non-significant increase of 0.0005 (-0.0030 to 0.0041; P=0.776). The 
continuous NRI was 30.2% (1.1 to 59.2%, P=0.042). 
In separate analyses for out-of-hospital SCDs and non-SCDs, there was no significant evidence of any 
association of Lp(a) with these outcomes (Appendix Supplement 2). 
 
4. Discussion 
In this population of middle-aged men without a history of HF and cardiac arrhythmias at baseline, we 
observed an increase in risk of SCD with increasing levels of Lp(a), though further work is required to 
determine whether a curvilinear or log-linear shape would better describe the relationship.  The 
association remained consistent after adjustment for several established risk factors, other potential 
confounders, and on accounting for incident coronary events during follow-up. The overall findings did 
not vary importantly across several subgroups. Our reproducibility studies of Lp(a) indicate that Lp(a) 
concentration is consistent within individuals over several years. Addition of information on plasma Lp(a) 
measurements to several established risk factors for SCD, did not incrementally improve SCD risk 
prediction, but yielded a significant improvement in reclassification. Finally, no significant associations 
were observed for the outcomes of out-of-hospital SCDs and non-SCDs.  
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4.1. Comparison with previous work  
It is not possible to compare the current findings in the context of previous work, as a we were unable 
to locate any published reports that have evaluated the prospective association between Lp(a) levels and 
SCD events.  However, several epidemiological and genetic studies have consistently and robustly shown 
that elevated Lp(a) is independently associated with CVD.[2-4] This association has been demonstrated 
for CVD specific endpoints such as acute myocardial infarction,[4] CHD,[28] carotid atherosclerosis,[29] 
ischemic stroke,[30] aortic valve stenosis,[31] and heart failure.[5] There is accruing evidence suggesting 
that these associations are also causal.[4, 31] Our novel findings of a robust independent association 
between elevated Lp(a) and risk of SCD is therefore not surprising, given that SCD and these CVD 
outcomes share many common risk factors. Indeed, coronary artery disease is the most common 
underlying cause of SCD in the general population.[8] However, given that this is the first prospective 
study to evaluate this association, other large-scale prospective studies are still needed to confirm the 
current findings. 
 
4.2. Possible explanations for findings 
Consistent with results observed for studies that have evaluated other cardiovascular outcomes, [2, 5] 
the pathophysiological mechanisms of action underlying our findings of a continuous and independent 
association between Lp(a) and SCD may relate to the pro-atherogenic, prothrombotic, and pro-
inflammatory properties of Lp(a).[6] Elevated Lp(a) is highly atherogenic through its low-density 
lipoprotein (LDL) component.[6] Indeed, experimental data has demonstrated the presence of Lp(a) in 
human atherosclerotic plaques,[32] which also provides evidence that Lp(a) is involved in the 
development of atherosclerotic lesions.[6] Thus, via its involvement in atheromatous plaque 
formation,[33, 34] Lp(a) may also cause acute myocardial ischemia, which is the most common trigger 
for fatal arrhythmias.[35] Lipoprotein(a) may inhibit fibrinolysis and promote thrombosis through 
competitive inhibition of plasmin generation and inactivation of the tissue factor pathway inhibitor.[36, 
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37] Lipoprotein(a) is able to mediate pro-inflammatory effects via its carriage of oxidized phospholipids, 
which are also known to be pro-atherogenic.[38] The atherosclerotic lesions and vulnerable plaques found 
in majority of cases of SCD have been found to be characterised by pathological signs of 
inflammation.[39] Lipoprotein(a) has also been implicated in macrophage foam cell formation, smooth 
muscle cell proliferation, plaque inflammation, and instability, which are key stages in the development 
of vulnerable atherosclerotic lesions.[36, 37] Liporotein(a) may also promote SCD via an increased risk 
of CHD; however, our analysis involved adjustment for prevalent CHD and our results remained robust 
on accounting for incident nonfatal CHD events during follow-up. We also excluded the first five years of 
follow-up thus minimizing the possibility of SCDs due to undiagnosed CHD. Further research is needed 
to help unravel the mechanistic pathways of Lp(a) in the pathogenesis of SCD.  
The findings of a continuous and independent association between Lp(a) levels and SCD risk are 
consistent with the indication of a causal relationship, but this requires robust evidence from randomized 
controlled trials. However, such trials may not enable causal inferences, as pharmacological agents [such 
as niacin, cholesteryl ester transfer protein (CETP) inhibitors, PCSK9 inhibitors, and antisense 
oligonucleotides] that are able to modify levels of Lp(a),[40] also influence concentrations of other 
lipoproteins (HDL-C, LDL-cholesterol, triglycerides, apo B100, and oxidised phospholipids).[41, 42] In 
the absence of clinical trials however, Mendelian randomisation (MR) studies of genetic variants 
specifically related to Lp(a) levels may provide another route to assess causality.[43] Plasma levels of 
Lp(a) are primarily genetically determined by polymorphisms in the LPA gene which code for the apo(a) 
moiety of Lp(a). Genetic variants including the kringle IV repeats at this locus, which have pronounced 
effects on Lp(a) concentrations,[44] have been used to assess the causal role of Lp(a) in CVD outcomes 
using MR approaches.[3-5]  
 
4.3. Implications of findings  
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Our findings are novel and highlight a clear and independent link between elevated Lp(a) levels and 
the risk of SCD in the general population and suggest that Lp(a) might modify the risk of SCD. Though 
there has been considerable debate and interest in the therapeutic modulation of Lp(a) levels, there is 
currently lack of clinical evidence that lowering of Lp(a) levels would decrease cardiovascular risk. 
Reasons for this include: (i) it is estimated that up to about 90% of the variation in Lp(a) levels may be 
due to genetic factors, making it one of the most important genetic risk factor for CVD.[45] As Lp(a) 
levels are primarily determined by genetic factors, its circulating levels are not influenced by dietary or 
environmental effects. Evidently, interventions such as nutritional and lifestyle modification have not 
shown any benefits in decreasing levels of Lp(a); (ii) in addition, given that interventions that specifically 
lower Lp(a) levels are currently not available, it has been difficult to perform intervention trials to 
establish the clinical benefit of lowering levels of Lp(a); and (iii) even though novel pharmacological 
agents such as niacin, mipomersen, PCSK9, and CETP inhibitors, do significantly lower Lp(a) levels, the 
reductions do not translate into clinical benefit on CVD outcomes[46, 47] or may not actually be related 
to the effects of Lp(a) lowering.[48] Irrespective of these shortcomings and still not fully acknowledged 
as a CVD risk factor in clinical practice, plasma Lp(a) is still regarded as a promising though unproven 
strategy for the prevention of major cardiovascular outcomes such as SCD. Though there is no unanimous 
agreement by guideline bodies as to when to measure Lp(a) and how to treat elevated levels, advice by 
expert panels of guideline bodies such as the European Atherosclerosis Society, National Lipid 
Association, and the National Cholesterol Education Program Adult Treatment Panel, have stressed the 
need to screen for elevated Lp(a) levels in patients at moderate- to high-risk of CVD/CHD and 
modulating levels to desirable levels of < 50 mg/dl with the use of niacin.[49-51] In the absence of (i) 
specific guideline recommendations on when and how to treat Lp(a) levels; (ii) promising new drugs that 
are still being tested;[52] and (iii) trials in patients with isolated Lp(a) elevations which will show a 
clinical benefit on cardiovascular outcomes; a major hope for isolated lowering of Lp(a) levels with 
potential clinical benefit on cardiovascular outcomes has been demonstrated in recent lipoprotein 
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apheresis studies.[53, 54] Finally, though addition of plasma Lp(a) did not significantly improve SCD risk 
prediction beyond established risk factors in this population, it does not rule out the potential for Lp(a) 
assays to be used in the identification of individuals at high risk for SCD.  We observed a net 
reclassification improvement and our risk prediction analyses were limited, as we did not have complete 
measurements on some other risk markers (e.g., ECG parameters, measures of heart rate variability, 
measures of ejection fraction, and angiographic findings) used in clinical risk prediction algorithms for 
SCD.[55, 56] The potential usefulness of Lp(a)  in SCD risk prediction deserves further investigation. 
 
4.4. Strengths and limitations  
There are several notable strengths of the current study that deserve consideration. This is the first 
prospective evaluation of the association between circulating plasma Lp(a) levels and the risk of SCD. 
Our analyses were based on a large cohort that was selected to be a nationally representative population-
based sample of middle-aged Finnish men. The cohort was well characterised, involved a high response 
rate, involved a long follow-up period, and there were no losses during follow-up, minimising the risk of 
selection bias. Participants in the KIHD cohort have been annually monitored using established databases 
for outcome events. We had access to a comprehensive panel of lifestyle and biological markers, which 
allowed adequate adjustment for potential confounding, enabling reliable assessments of the associations. 
Repeat measurements of Lp(a) several years apart enabled correction for long-term within-person 
variability in Lp(a) levels. Indeed, reproducibility substudies of Lp(a) in the KIHD were consistent with 
findings from Emerging Risk Factors Collaboration.[2] Our study had a number of limitations which also 
deserve consideration. We included a relatively small number of SCDs, therefore the need to confirm 
these findings in larger-scale studies with more SCD events. Though we adjusted for several confounders, 
there is always the possibility of residual confounding, which could in part explain the association 
between Lp(a) and SCD. The KIHD study included only middle-aged men based on a predominantly 
white-European population from eastern Finland and given that plasma levels of Lp(a) vary substantially 
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among persons and populations,[57] our findings therefore cannot be generalizable to women, the young, 
elderly, and other ethnicities.  
 
Conclusions 
This prospective study shows a continuous and independent association between Lp(a) levels and risk 
of SCD. However, further research is needed to replicate these findings and assess the potential clinical 
utility of Lp(a) as a risk assessment tool or validated causal therapeutic target for SCD events.  
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Figure 1: Cumulative hazard curves for sudden cardiac death by quartiles of lipoprotein(a) 
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The median Lp(a) level (mg/dl) was 1.68 (range 0.84-2.92) for the lowest quartile; 6.16 (range 4.83-7.63) 
for the second quartile; 14.79 (range 12.13-18.26) for the third quartile; and 37.35 (range 28.46-51.72) for 
the top quartile; Lp(a), lipoprotein(a); SCD, sudden cardiac death 
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Figure 2:  Hazard ratios for sudden cardiac death by quartiles of baseline levels of lipoprotein(a) 
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Hazard ratios were adjusted for age, body mass index, systolic blood pressure, prevalent coronary heart 
disease, smoking status, history of diabetes, left ventricular hypertrophy, history of hypertension, and use 
of medications (antihypertensive agents and lipid-lowering drugs); Lp(a), lipoprotein(a) 
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Figure 3: Hazard ratios for baseline levels of lipoprotein(a) and sudden cardiac death risk by several 
participant level characteristics 
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Hazard ratios were adjusted for age, body mass index, systolic blood pressure, prevalent coronary heart 
disease, smoking status, history of diabetes, left ventricular hypertrophy, history of hypertension, and use 
of medications (antihypertensive agents and lipid-lowering drugs); CHD, coronary heart disease; CI, 
confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; Lp(a), lipoprotein(a); SCD, sudden 
cardiac death; SD, standard deviation; *, P-value for interaction 
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Table 1: Baseline participant characteristics 
 
  
Overall (N=1,881) 
Mean (SD) or n (%) 
 
Without SCD (N=1,740) 
Mean (SD) or n (%) 
 
With SCD (N=141) 
Mean (SD) or % 
 
 
P-value 
Loge lipoprotein(a) (mg/dl) 2.16 (1.27) 2.15 (1.26) 2.31 (1.36) 0.107 
     
Questionnaire/Prevalent conditions     
Age at survey (years) 53 (5) 52 (5) 54 (4) 0.001 
Alcohol consumption (g/week) 76.0 (141.6) 74.3 (142.1) 97.3 (133.3) 0.063 
History of diabetes 87 (4.6) 73 (4.2) 14 (9.9) 0.002 
Current smokers 608 (32.3) 544 (31.3) 64 (45.4) 0.001 
Left ventricular hypertrophy 21 (1.1) 19 (1.1) 2 (1.4) 0.723 
History of hypertension 541 (28.8) 496 (28.5) 45 (31.9) 0.390 
History of CHD 402 (21.4) 343 (19.7) 59 (41.8) < 0.001 
Use of anti-hypertensives 345 (18.3) 304 (17.5) 41 (29.1) 0.001 
Medication for dyslipidemia 11 (0.6) 11 (0.6) 0 (0.0) 0.344 
     
Physical measurements     
BMI (kg/m2) 26.8 (3.5) 26.7 (3.4) 28.2 (4.2) < 0.0001 
SBP (mmHg) 134 (16) 134 (16) 139 (18) 0.0003 
DBP (mmHg) 89 (10) 89 (10) 91 (10) 0.009 
Resting heart rate (bpm) 62.5 (10.7) 62.3 (10.6) 64.5 (11.7) 0.025 
     
Lipid markers     
Total cholesterol (mmol/l) 5.92 (1.09) 5.89 (1.08) 6.19 (1.13) 0.002 
HDL-C (mmol/l) 1.29 (0.30) 1.29 (0.30) 1.23 (0.26) 0.018 
Loge triglycerides (mmol/l) 0.11 (0.50) 0.10 (0.50) 0.21 (0.56) 0.012 
     
Metabolic and inflammatory 
markers 
    
Fasting plasma glucose (mmol/l) 5.32 (1.19) 5.29 (1.12) 5.69 (1.83) 0.0001 
Serum creatinine (µmol/1) 89.4 (22.6) 89.3 (13.3) 91.0 (67.4) 0.409 
Loge CRP (mg/l) 0.29 (0.95) 0.26 (0.94) 0.66 (0.98) < 0.0001 
 
 BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein 
cholesterol; SD, standard deviation; SBP, systolic blood pressure; SCD, sudden cardiac death 
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Table 2: Cross-sectional correlates of lipoprotein(a) 
 
Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in Lp(a) levels 
per 1 SD higher or compared to reference 
category of correlate‡ 
Loge lipoprotein(a) (mg/dl) - - 
   
Questionnaire/Prevalent conditions   
Age at survey (years) 0.02 (-0.03, 0.06) 2% (-4, 8) 
Alcohol consumption (g/week) 0.00 (-0.04, 0.05) 0% (-5, 6) 
History of diabetes   
    No - Ref 
    Yes - -31% (-47, -9)* 
Smoking status   
    Other - Ref 
    Current - 3% (-9, 16) 
Left ventricular hypertrophy   
    No - Ref 
    Yes - 33% (-23, 129) 
History of hypertension   
    No - Ref 
    Yes - -9% (-20, 3) 
History of CHD   
    No - Ref 
    Yes - -3% (-16, 11) 
Use of anti-hypertensives   
    No - Ref 
    Yes - -14 (-26, 0) 
Medication for dyslipidemia   
    No - Ref 
    Yes - 40% (-34, 197) 
   
Physical measurements   
BMI (kg/m2) -0.10 (-0.15, -0.06)*** -12% (-17, -7)*** 
SBP (mmHg) -0.02 (-0.07, 0.02) -3% (-8, 3) 
DBP (mmHg) -0.04 (-0.08, 0.01) -5% (-10, 1) 
Resting heart rate (bpm) 0.01 (-0.03, 0.06) 1% (-4, 7) 
   
Lipid markers   
Total cholesterol (mmol/l) 0.12 (0.08, 0.17)*** 17% (11, 24)*** 
HDL-C (mmol/l) 0.00 (-0.05, 0.05) 0% (-6, 6) 
Loge triglycerides (mmol/l) -0.05 (-0.10, -0.01)* -6% (-11, -1)* 
   
Metabolic and inflammatory markers   
Fasting plasma glucose (mmol/l) -0.08 (-0.12, -0.03)** -9% (-14, -4)** 
Serum creatinine (µmol/1) 0.04 (-0.00, 0.09) 6% (-0, 12) 
Loge C-reactive protein (mg/l) 0.10 (0.06, 0.15)** 14% (8, 21)*** 
 
 BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; SD, standard 
deviation; SBP, systolic blood pressure; asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001, †Pearson 
correlation coefficients between loge Lp(a) and the row variables; ‡, Percentage change in Lp(a) levels per 1-SD increase in the row variable (or 
for categorical variables, the percentage difference in mean Lp(a) levels for the category versus the reference) adjusted for age  
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Table 3: Association of baseline plasma lipoprotein(a) concentrations with sudden cardiac death 
 
Lp(a) concentration 
(mg/dl) 
Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 141 / 1881 1.24 (1.05 to 1.47) 0.013 1.23 (1.04 to 1.46) 0.018 1.20 (1.01 to 1.43) 0.039 1.21 (1.01 to 1.44) 0.039 
Q1 (< 3.84) 34 / 471 ref  ref  ref  ref  
Q2 (3.85-9.66) 26 / 471 1.03 (0.61 to 1.74) 0.902 1.01 (0.60 to 1.70) 0.980 0.98 (0.58 to 1.65) 0.931 1.02 (0.60 to 1.72) 0.941 
Q3 (9.67-22.04) 33 / 469 1.17 (0.72 to 1.90) 0.534 1.16 (0.71 to 1.88) 0.561 1.12 (0.69 to 1.83) 0.655 1.13 (0.69 to 1.85) 0.629 
Q4 (≥ 22.05) 48 / 470 1.84 (1.17 to 2.88) 0.008 1.79 (1.14 to 2.82) 0.011 1.69 (1.07 to 2.67) 0.025 1.72 (1.09 to 2.73) 0.021 
 
CI, confidence interval; HR, hazard ratio; Lp(a), lipoprotein(a); SD, standard deviation 
Model 1: Adjusted for age, BMI, systolic blood pressure, prevalent coronary heart disease, smoking status, history of diabetes mellitus, left ventricular hypertrophy, history of 
hypertension, and use of medications (antihypertensive agents and lipid-lowering drugs) 
Model 2: Model 1 plus alcohol consumption, resting heart rate, triglycerides, total cholesterol, and high-density lipoprotein cholesterol 
Model 3: Model 2 plus C-reactive protein 
Model 4: Model 3 plus incident coronary heart disease as a time-dependent covariate 
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Appendix 1: Association of Usual Levels of Plasma Lipoprotein(a) With Sudden Cardiac Death 
 
Lp(a) concentration 
(mg/dl) 
Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 141 / 1881 1.29 (1.06 to 1.59) 0.013 1.28 (1.04 to 1.57) 0.018 1.24 (1.01 to 1.53) 0.039 1.24 (1.01 to 1.53) 0.039 
Q1 (< 3.84) 34 / 471 ref  ref  ref  ref  
Q2 (3.85-9.66) 26 / 471 1.04 (0.56 to 1.93) 0.902 1.01 (0.54 to 1.88) 0.980 0.97 (0.52 to 1.81) 0.931 1.02 (0.55 to 1.91) 0.941 
Q3 (9.67-22.04) 33 / 469 1.20 (0.67 to 2.15) 0.534 1.19 (0.66 to 2.12) 0.561 1.14 (0.64 to 2.05) 0.655 1.15 (0.64 to 2.07) 0.629 
Q4 (≥ 22.05) 48 / 470 2.06 (1.21 to 3.53) 0.008 2.01 (1.17 to 3.44) 0.011 1.87 (1.08 to 3.22) 0.025 1.91 (1.10 to 3.30) 0.021 
 
CI, confidence interval; HR, hazard ratio; Lp(a), lipoprotein(a); SD, standard deviation 
Model 1: Adjusted for age, BMI, systolic blood pressure, prevalent coronary heart disease, smoking status, history of diabetes mellitus, left ventricular hypertrophy, history of 
hypertension, and use of medications (antihypertensive agents and lipid-lowering drugs) 
Model 2: Model 1 plus alcohol consumption, resting heart rate, triglycerides, total cholesterol, and high-density lipoprotein cholesterol 
Model 3: Model 2 plus C-reactive protein 
Model 54 Model 3 plus incident coronary heart disease as a time-dependent covariate 
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Appendix 2: Associations of Baseline Lipoprotein(a) Concentrations With Out-of-Hospital Sudden Cardiac Deaths and Non-Sudden Cardiac 
Deaths 
 
Models Out-of-hospital sudden cardiac 
death 
 Non-sudden cardiac death  
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
 1,881 participants and  
109 cases 
 1,881 participants and  
68 cases 
 
Model 1 1.17 (0.97 to 1.43) 0.097 1.02 (0.80 to 1.30) 0.897 
Model 2 1.17 (0.96 to 1.42) 0.112 1.02 (0.80 to 1.30) 0.877 
Model 3 1.16 (0.95 to 1.41) 0.140 1.00 (0.78 to 1.28) 0.998 
Model 4 1.16 (0.95 to 1.41) 0.143 0.99 (0.77 to 1.27) 0.928 
 
CI, confidence interval; HR, hazard ratio; Hazard ratios are per 1 standard deviation (3.56-fold) increase in lipoprotein(a) levels 
Model 1: Adjusted for age, BMI, systolic blood pressure, prevalent coronary heart disease, smoking status, history of diabetes mellitus, left ventricular hypertrophy, history of 
hypertension, and use of medications (antihypertensive agents and lipid-lowering drugs) 
Model 2: Model 1 plus alcohol consumption, resting heart rate, triglycerides, total cholesterol, and high-density lipoprotein cholesterol 
Model 3: Model 2 plus C-reactive protein 
Model 4: Model 3 plus incident coronary heart disease as a time-dependent covariate 
 
 
